Antihypertensive Drugs Market by Drug Class (Alpha-Blockers, Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers), Form (Intravenous Injections, Oral Tablets/Capsules, Transdermal Patches), Indication, Distribution Channel, End-User - Global Forecast 2024-2030
The Antihypertensive Drugs Market size was estimated at USD 24.70 billion in 2023 and expected to reach USD 25.76 billion in 2024, at a CAGR 4.66% to reach USD 33.99 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Antihypertensive Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antihypertensive Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Antihypertensive Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alembic Pharmaceuticals Limited, Alkem Laboratories, Apikos Pharma, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Centurion Remedies Private Limited, Daiichi Sankyo Co., Ltd., Dr. Reddy's Laboratories, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Glenmark Pharmaceuticals Ltd., Johnson & Johnson Services, Inc., Lupin Ltd., Merck & Co., Inc., Novartis AG, Sanofi S.A., Saphnix Lifesciences, Schwitz Biotech, Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, and Zydus Lifesciences Limited.
Market Segmentation & Coverage
This research report categorizes the Antihypertensive Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
Drug Class
Alpha-Blockers
Angiotensin Converting Enzyme Inhibitors
Angiotensin Receptor Blockers
Beta-Blockers
Calcium Channel Blockers
Diuretics
Renin Inhibitors
Vasodilators
Form
Intravenous Injections
Oral Tablets/Capsules
Transdermal Patches
Indication
Primary Hypertension
Secondary Hypertension
Distribution Channel
Offline
Online
End-User
Home Care Facilities
Hospitals & Clinics
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom The report offers valuable insights on the following aspects:
Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
What is the market size and forecast of the Antihypertensive Drugs Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antihypertensive Drugs Market?
What are the technology trends and regulatory frameworks in the Antihypertensive Drugs Market?
What is the market share of the leading vendors in the Antihypertensive Drugs Market?
Which modes and strategic moves are suitable for entering the Antihypertensive Drugs Market?
Note: PDF & Excel + Online Access - 1 Year
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Antihypertensive Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Surging prevalence of hypertension, along with the growing geriatric population
5.1.1.2. Increase in healthcare expenditure worldwide
5.1.1.3. Growing consumer awareness of early diagnosis and treatment
5.1.2. Restraints
5.1.2.1. Stringent approval process and huge costs involved in drug development
5.1.3. Opportunities
5.1.3.1. Introduction of a new class of antihypertensive drugs
5.1.3.2. Surge in approvals of novel drugs from regulatory bodies
5.1.4. Challenges
5.1.4.1. Concern regarding adverse health outcomes of antihypertensive drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Antihypertensive Drugs Market, by Drug Class
6.1. Introduction
6.2. Alpha-Blockers
6.3. Angiotensin Converting Enzyme Inhibitors
6.4. Angiotensin Receptor Blockers
6.5. Beta-Blockers
6.6. Calcium Channel Blockers
6.7. Diuretics
6.8. Renin Inhibitors
6.9. Vasodilators
7. Antihypertensive Drugs Market, by Form
7.1. Introduction
7.2. Intravenous Injections
7.3. Oral Tablets/Capsules
7.4. Transdermal Patches
8. Antihypertensive Drugs Market, by Indication
8.1. Introduction
8.2. Primary Hypertension
8.3. Secondary Hypertension
9. Antihypertensive Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Offline
9.3. Online
10. Antihypertensive Drugs Market, by End-User
10.1. Introduction
10.2. Home Care Facilities
10.3. Hospitals & Clinics
11. Americas Antihypertensive Drugs Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Antihypertensive Drugs Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Antihypertensive Drugs Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. Abbott Laboratories
15.1.2. Alembic Pharmaceuticals Limited
15.1.3. Alkem Laboratories
15.1.4. Apikos Pharma
15.1.5. AstraZeneca PLC
15.1.6. Bayer AG
15.1.7. Boehringer Ingelheim International GmbH
15.1.8. Centurion Remedies Private Limited
15.1.9. Daiichi Sankyo Co., Ltd.
15.1.10. Dr. Reddy's Laboratories
15.1.11. F. Hoffmann-La Roche AG
15.1.12. Gilead Sciences, Inc.
15.1.13. Glenmark Pharmaceuticals Ltd.
15.1.14. Johnson & Johnson Services, Inc.
15.1.15. Lupin Ltd.
15.1.16. Merck & Co., Inc.
15.1.17. Novartis AG
15.1.18. Sanofi S.A.
15.1.19. Saphnix Lifesciences
15.1.20. Schwitz Biotech
15.1.21. Sun Pharmaceutical Industries Limited
15.1.22. Takeda Pharmaceutical Company Limited
15.1.23. Teva Pharmaceutical Industries Ltd.
15.1.24. United Therapeutics Corporation
15.1.25. Zydus Lifesciences Limited
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
FIGURE 1. ANTIHYPERTENSIVE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2023 VS 2030